{
"@context": "http://schema.org",
"@type": "Collection",
"@id": "https://doi.org/10.25384/sage.c.6384059",
"url": "https://sage.figshare.com/collections/Plasma_neurofilament_light_chain_in_children_with_relapsing_MS_receiving_teriflunomide_or_placebo_A_post_hoc_analysis_of_the_randomized_TERIKIDS_trial/6384059",
"additionalType": "Collection",
"name": "Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomized TERIKIDS trial",
"author": [
{
"name": "Jens Kuhle",
"givenName": "Jens",
"familyName": "Kuhle",
"affiliation": {
"@type": "Organization",
"@id": "https://ror.org/02s6k3f65",
"name": "University of Basel"
}
},
{
"name": "Tanuja Chitnis",
"givenName": "Tanuja",
"familyName": "Chitnis",
"affiliation": [
{
"@type": "Organization",
"@id": "https://ror.org/03vek6s52",
"name": "Harvard University"
},
{
"@type": "Organization",
"@id": "https://ror.org/04b6nzv94",
"name": "Brigham and Women's Hospital"
}
]
},
{
"name": "Brenda Banwell",
"givenName": "Brenda",
"familyName": "Banwell"
},
{
"name": "Marc Tardieu",
"givenName": "Marc",
"familyName": "Tardieu"
},
{
"name": "Douglas L Arnold",
"givenName": "Douglas L",
"familyName": "Arnold"
},
{
"name": "Andreea M Rawlings",
"givenName": "Andreea M",
"familyName": "Rawlings"
},
{
"name": "Svend S Geertsen",
"givenName": "Svend S",
"familyName": "Geertsen"
},
{
"name": "Alex L Lublin",
"givenName": "Alex L",
"familyName": "Lublin"
},
{
"name": "Stephane Saubadu",
"givenName": "Stephane",
"familyName": "Saubadu"
},
{
"name": "Philippe Truffinet",
"givenName": "Philippe",
"familyName": "Truffinet"
},
{
"name": "Ludwig Kappos",
"givenName": "Ludwig",
"familyName": "Kappos"
}
],
"description": "Background:The phase 3 TERIKIDS study demonstrated efficacy and manageable safety for teriflunomide versus placebo in children with relapsing multiple sclerosis (RMS).Objective:Evaluate plasma neurofilament light chain (pNfL) concentrations in TERIKIDS.Methods:Patients received placebo or teriflunomide (14 mg adult equivalent) for up to 96 weeks in the double-blind (DB) period. In the open-label extension (OLE), all patients received teriflunomide until up to 192 weeks after randomization. pNfL was measured using single-molecule array assay (Simoa® NF-light™).Results:Baseline mean age was 14.5 years; 69.4% were female. Baseline geometric least square mean pNfL levels were similar for teriflunomide (n = 78) and placebo (n = 33) patients (19.83 vs 18.30 pg/mL). Over the combined DB and OLE periods, pNfL values were lower for teriflunomide versus placebo (analysis of variance p < 0.01; Week 192: 10.61 vs 17.32 pg/mL). Observed between-group pNfL differences were attenuated upon adjustment for gadolinium (Gd)-enhancing or new/enlarged T2 lesion counts at DB Week 24. Higher baseline pNfL levels were associated with shorter time since first MS symptom onset, higher baseline Gd-enhancing lesion counts and T2 lesion volume, and increased hazard of high magnetic resonance imaging activity or clinical relapse during the DB period.Conclusion:Teriflunomide treatment was associated with significantly reduced pNfL levels in children with RMS.ClinicalTrials.gov identifier:NCT02201108.",
"license": "https://creativecommons.org/licenses/by/4.0/legalcode",
"keywords": "110904 Neurology and Neuromuscular Diseases, FOS: Clinical medicine, 111702 Aged Health Care, FOS: Health sciences",
"dateCreated": "2023-01-13",
"datePublished": "2023",
"dateModified": "2023-01-13",
"@reverse": {
"isBasedOn": {
"@id": "https://doi.org/10.1177/13524585221144742",
"@type": "ScholarlyArticle"
}
},
"schemaVersion": "http://datacite.org/schema/kernel-4",
"publisher": {
"@type": "Organization",
"name": "SAGE Journals"
},
"provider": {
"@type": "Organization",
"name": "datacite"
}
}